News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Cortex Pharmaceuticals, Inc.'s (COR) CEO To Speak At The Techvest Global Healthcare Conference In London On May 13, 2004

10/19/2005 5:11:06 PM

IRVINE, Calif.--(BUSINESS WIRE)--April 29, 2004--Cortex Pharmaceuticals, Inc., (AMEX: COR - News), announced that Roger G. Stoll, Ph.D., Chairman, President and CEO has accepted an invitation to speak at the Rodman & Renshaw Techvest Global Healthcare Conference on Thursday, May 13th at 9:25 AM BST. Cortex is one of 150 invited public and private companies to present at this conference to be held at the Claridge's Hotel in London on May 12-14, 2004.

Dr. Stoll will provide an update on Cortex's AMPAKINE® drug development program, including the progress made on their Phase I compound, CX717. A review of the Company's current financial status and what their "Orphan Drug" business strategy could potentially mean to shareholders over the next several years will also be discussed.

A live audio webcast of the presentation can be accessed by logging into the website at An audio replay of the presentation will also be available for 30 days after the conference.

About Cortex Pharmaceuticals:

Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. The Company is pioneering a class of proprietary pharmaceuticals called AMPAKINE compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer's disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain's neurotransmitter system. These imbalances may be improved by using the AMPAKINE technology. Cortex has alliances with N.V. Organon for the treatment of schizophrenia and depression and with Les Laboratoires Servier for the development of AMPAKINE compounds to treat the neurodegenerative effects associated with aging and disease, including Mild Cognitive Impairment, Alzheimer's disease and anxiety disorders. (


Cortex Pharmaceuticals, Inc. Roger G. Stoll, Ph.D., 949-727-3157 or

The Investor Relations Group Jane Lin/Dian Griesel, Ph.D., 212-825-3210

Source: Cortex Pharmaceuticals, Inc.

Read at

comments powered by Disqus